Delivery Order SPE2DR25D1201-SPE2DR26FAKRA
- Not listed
- On January 22, 2026, the Defense Logistics Agency awarded a delivery order valued at $5,149.59 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside contract represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999.99 billion through December 2026), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare...
- On January 28, 2026, the Defense Logistics Agency awarded a delivery order valued at $42,073.95 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml SureClick auto-injectors. The contract, which is not set aside and competitively awarded, represents a firm fixed-price delivery order with an ultimate completion date of January 29, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, executed this delivery order as a child contract under its parent...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $28,041.73 for Enbrel 50 mg/mL syringes on January 26, 2026, with an ultimate completion date of January 27, 2026. The award was made by the Defense Logistics Agency (DLA), a defense agency responsible for supplying military and federal healthcare systems. This delivery order represents a firm fixed-price contract with no set-aside designation,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on January 22, 2026, for Enbrel 50 mg/ml syringes valued at $13,239.67. The order is non-competitive and carries a firm fixed price structure with an ultimate completion date of January 23, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 21, 2026, for the supply of ENBREL 50 MG/ML syringes valued at $33,891.70. This firm fixed-price delivery order is set to be completed by January 22, 2026, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The award was issued on a non-set-aside, competitive basis, reflecting the company's capability to meet federal...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,579.33 by the Defense Logistics Agency on May 30, 2025, for the supply of Enbrel 50 mg/ml syringes. This non-set-aside, competitively awarded contract carries a firm fixed price structure with a completion date of June 2, 2025. The work will be performed at AmerisourceBergen's Conshohocken facility. This delivery order represents a child...
- On January 20, 2026, the Defense Logistics Agency awarded a delivery order valued at $18,963.86 to Amerisourcebergen Drug Corp for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by January 21, 2026, and will be fulfilled at the vendor's Conshohocken, Pennsylvania location. Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as a critical pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $9,651.82 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes, with performance at the contractor's facility in Conshohocken, Pennsylvania. This award, issued on December 18, 2025, represents a firm fixed price delivery order with an ultimate completion date of December 19, 2025. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's qualification to compete for...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $31,538.23 by the Defense Logistics Agency (DLA) on December 1, 2025, for the supply of Enbrel 50 mg/mL syringes. The contract is classified as a child award under a larger Indefinite Delivery Contract vehicle and utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award status. Performance is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Enbrel 50 mg/ml syringes, with a contract ceiling value of $9,651.82. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the vendor's...
- SPE2DR25D1201Indefinite Delivery Contract
- SPE2DR25D1201-SPE2DR26FAKRADelivery Order
On January 28, 2026, the Defense Logistics Agency awarded a $30,297.86 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes. This firm fixed-price contract, with an ultimate completion date of January 29, 2026, carries no set-aside designation and was competitively awarded. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal agencies, particularly the Department of Defense and Veterans Affairs health systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive vehicle enables the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. The parent company, Cencora, Inc., also maintains a significant $999,999,999.00 IDC with DLA through December 31, 2031, underscoring the organization's critical role in the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.3k | 1/27/26 |